Free Trial
→ Wall Street legend reveals his top AI stock before Oct. 20 (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:HIND

Vyome Q2 2026 Earnings Results & Report

$1.97 -0.04 (-1.99%)
Closing price 10/13/2026 03:59 PM Eastern
Extended Trading
$1.96 -0.01 (-0.71%)
As of 08:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vyome reported Q2 2026 earnings on August 12, 2026. The company reported EPS of -$0.10, while revenue was $0.27 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Vyome EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Vyome Revenue Results

Actual Revenue
$0.27 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Vyome's Q2 2026 Press ReleasePress Release
(8-K)
Vyome's Q2 2026 Quarterly reportQuarterly report
(10-Q)

Vyome Q2 2026 Earnings FAQ

Vyome (NASDAQ:HIND) reported earnings of -$0.10 per share for Q2 2026. The report was announced on Wednesday, August 12, 2026.

Vyome reported revenue of $0.27 million for Q2 2026.

Vyome Earnings Headlines

Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vyome-receives-uspto-notice-allowance-120000203.html
Average price target for Vyome Holdings decreased by 23.19% to $9.01
September 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/average-price-target-for-vyome-holdings-decreased-by-23-19-to-9-01/ar-AA2coLsN
How one AI fund pays investors every Thursday
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling shares or trading options, but simply by holding the fund and letting it pay out cash every Thursday. That works out to a 34% annualized distribution rate, even though the underlying AI stocks pay no dividends themselves. Tim Plaehn, Chief Income Strategist at Investors Alley, breaks down exactly how the fund generates these weekly payouts.tc pixel
October 14 at 1:00 AM  |  Investors Alley (Ad)
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
September 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vyome-appoints-experienced-public-company-120000912.html
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
September 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260914390030/en/vyome-appoints-experienced-public-company-finance-executive-jerry-leonard-as-chief-financial-officer/
Chardan Capital initiates coverage of Vyome Holdings (HIND) with buy rating
September 4, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/chardan-capital-initiates-coverage-of-vyome-holdings-hind-with-buy-rating/ar-AA2byxaJ
See More Vyome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vyome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vyome and other key companies, straight to your email.

About Vyome

Vyome (NASDAQ:HIND) is a biotechnology company focused on developing therapies for dermatological conditions. Its research programs are centered on skin diseases involving inflammation, microbial imbalance and antibiotic resistance, with the goal of creating targeted treatments for patients who have limited options.

The company’s pipeline has included topical therapies for acne and other inflammatory skin disorders. Among its reported programs is VB-1953, an investigational topical treatment designed to address acne-causing bacteria while potentially reducing concerns associated with conventional broad-spectrum antibiotics. Vyome’s drug candidates remain subject to clinical development and regulatory review.

Vyome was established as a dermatology-focused biotechnology business with operations and research activities associated with the United States and India. Publicly available information about its current leadership, commercial products and geographic operations is limited, and the company’s development programs may change as clinical and regulatory work progresses.

View Vyome Profile
Earnings Tools